Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer

Chakra, Mohammad; Pujol, Jean Louis; Lamy, Pierre‐Jean; Bozonnat, Marie Cecile; Quantin, Xavier; Jacot, William; Daurès, Jean‐Pierre

doi:10.1097/jto.0b013e318187464e

Cited by 27 publications

(26 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These complex mechanisms influencing serum VEGF concentration might have contributed to the fact that we did not prove correlations between VEGF concentrations, and the effect of therapy and prognosis of survival time. The results of our study are in accordance with Chakra's et al [30] and Tas's et al [31] findings. These authors proved that a circulating serum vascular endothelial growth factor was not a prognostic factor of non-small cell lung cancer.…”

Section: Discussionsupporting

confidence: 83%

Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.

Naumnik

Nilklińska²,

Ossolińska³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:Recently, several reports have suggested that HMGB1 (the high-mobility group box-1) plays a key role in tumor angiogenesis through multiple mechanisms, including up-regulation of proangiogenic factors. This study was conducted to investigate the prognostic role and the effects of chemotherapy on serum (ELISA) angiogenic factors: HMGB1, survivin and VEGF (Vascular Endothelial Growth Factor) in patients with advanced stage non-small cell lung cancer (NSCLC). The study entered 40 patients (31 man) and 15 healthy volunteers (control group). Peripheral blood samples were taken before and after four cycles of chemotherapy. The mean serum HMGB1 and VEGF levels were significantly higher in patients with advanced NSCLC than in controls (p=0.024, p=0.028, respectively). The levels of survivin in NSCLC patients were comparable to controls. No correlation was found between HMGB1, survivin and VEGF concentrations and the histological type and staging of lung cancer. Similarly, no correlation was revealed between the concentrations of HMGB1, survivin and VEGF and the effect of chemotherapy. However, in patients with NSCLC, HMGB1 positevely correlated with survivin (R=0.814, p=0.007) before chemotherapy, and negatively with VEGF (R=-0.841, p=0.035) after chemotherapy. When the cut-off values of serum HMGB1, survivin and VEGF (2.38 ng/ml, 81.92 pg/ml, 443.26 pg/ml, respectively) were used, the prognoses of high and low groups were not different. Concluding, patients with NSCLC have a higher serum concentration of HMGB1 and VEGF, while survivin levels are comparable to healthy individuals. In our opinion, determination of HMGB1, survivin and VEGF concentrations has no clinical significance in the prognosis of the survival time in lung cancer.

show abstract

Section: Discussionsupporting

confidence: 83%

Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.

Naumnik

Nilklińska²,

Ossolińska³

et al. 2010

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

show abstract

“…In agreement with previous studies (Laack et al, 2002;Chakra et al, 2008). we found that a high serum VEGF level did not independently determine prognosis of lung cancer.But several other studies produced conflicting results (Kaya et al, 2004;Hasegawa et al, 2005).…”

Section: Discussionsupporting

confidence: 93%

Prognostic Values of VEGF and Endostatin with Malignant Pleural Effusions in Patients with Lung Cancer

Yu¹,

Lu²,

Xia³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aims: Angiogenesis is important in malignant pleural effusion (MPE) formation and it is regulated by a number of pro-and anti-angiogenic cytokines. The purpose of this study was to evaluate the prognostic value of angiogenic factor vascular endothelial growth factor (VEGF) and angiogenesis inhibitor endostatin in lung cancer patients with MPE, and investigate the relationship between these two kinds of agent. Methods: Using enzyme-linked immunoadsorbent assay, the concentrations of VEGF and endostatin were measured in pleural effusions (PE) and serum from a total of 70 lung cancer patients with MPE and 20 patients with tuberculosis. Results: Compared to patients with tuberculosis, the levels of VEGF and endostatin in both PE and serum were significantly higher in patients with lung cancer. There were statistically significant correlations between VEGF levels in PE and serum (r=0.696, p<0.001), endostatin levels in PE and serum (r=0.310, p=0.022), and VEGF and endostatin levels in PE (r=0.287, p=0.019). Cox multivariate analysis revealed that elevated pleural VEGF and endostatin levels and serum endostatin level were independent predictors of shorter overall survival. Conclusion: Both pro-and anti-angiogenic factors are likely contributors to PE formation. Our results suggest that the levels of VEGF and endostatin in PE, together with endostatin in serum, may be potential prognostic parameters for lung cancer patients with MPE.

show abstract

“…Some studies have indicated that pre-chemotherapy VEGF-A or sVEGFR-2 levels correlate with disease activity and prognosis [14]; however, other studies have produced inconclusive evidence concerning the reliability or pre- dictability of this correlation [17,44]. Hanrahan et al reported that low baseline circulating VEGF was associated with a better progression free survival in patients with advanced NSCLC treated with anti-angiogenic drugs [45].…”

Section: Discussionmentioning

confidence: 96%

Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC

et al. 2011

View full text Add to dashboard Cite

Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer

Cited by 27 publications

References 41 publications

Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.

Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.

Prognostic Values of VEGF and Endostatin with Malignant Pleural Effusions in Patients with Lung Cancer

Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC

Contact Info

Product

Resources

About